Key Takeaways
- Pfizer will end global development and commercialization of hemophilia B gene therapy Beqvez due to a lack of patient and doctor interest, terminating the last of its AAV gene therapy programs.
Less than two months after Pfizer opted to give up its rights to late-stage Sangamo Therapeutics-partnered hemophilia A gene therapy...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?